CA2536140A1 - Dosing schedule for erbb2 anticancer agents - Google Patents

Dosing schedule for erbb2 anticancer agents Download PDF

Info

Publication number
CA2536140A1
CA2536140A1 CA002536140A CA2536140A CA2536140A1 CA 2536140 A1 CA2536140 A1 CA 2536140A1 CA 002536140 A CA002536140 A CA 002536140A CA 2536140 A CA2536140 A CA 2536140A CA 2536140 A1 CA2536140 A1 CA 2536140A1
Authority
CA
Canada
Prior art keywords
methyl
inhibitor
yloxy
pyridin
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002536140A
Other languages
English (en)
French (fr)
Inventor
Samit Kumar Bhattacharya
Richard Damian Connell
James Dale Moyer
Jitesh Pranlal Jani
Dennis Alan Noe
Stefanus Johannes Steyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2536140A1 publication Critical patent/CA2536140A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002536140A 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents Abandoned CA2536140A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18
US60/495,919 2003-08-18
PCT/IB2004/002580 WO2005016347A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Publications (1)

Publication Number Publication Date
CA2536140A1 true CA2536140A1 (en) 2005-02-24

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002536140A Abandoned CA2536140A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Country Status (18)

Country Link
US (1) US20050119288A1 (OSRAM)
EP (1) EP1658080A1 (OSRAM)
JP (1) JP2007502807A (OSRAM)
KR (2) KR20060037447A (OSRAM)
CN (1) CN1838959A (OSRAM)
AR (1) AR045268A1 (OSRAM)
AU (1) AU2004264726A1 (OSRAM)
BR (1) BRPI0413745A (OSRAM)
CA (1) CA2536140A1 (OSRAM)
CO (1) CO5670356A2 (OSRAM)
IL (1) IL173127A0 (OSRAM)
MX (1) MXPA06001989A (OSRAM)
NO (1) NO20061252L (OSRAM)
RU (1) RU2328287C2 (OSRAM)
SG (1) SG135193A1 (OSRAM)
TW (1) TW200522966A (OSRAM)
WO (1) WO2005016347A1 (OSRAM)
ZA (1) ZA200600517B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210787B2 (en) 2002-02-01 2009-04-23 Medinol Ltd. Phosphorus-containing compounds & uses thereof
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
EP1660090B1 (en) * 2003-08-14 2012-11-21 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
JP4036885B2 (ja) 2003-09-19 2008-01-23 アストラゼネカ アクチボラグ キナゾリン誘導体
ME01267B (me) 2004-05-06 2013-06-20 Warner Lambert Co 4-fenilaminokinazolin-6-ilamidi
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
EP1896030A1 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
AU2006259261B2 (en) * 2005-06-16 2013-06-13 Myrexis, Inc. Pharmaceutical compositions and use thereof
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
EP2662082A1 (en) * 2005-11-14 2013-11-13 Ariad Pharmaceuticals, Incorporated Administration of mTOR inhibitors
PL2090575T3 (pl) 2005-11-15 2011-09-30 Array Biopharma Inc Sposoby i związki pośrednie do otrzymywania pochodnych N4-fenylo-chinazolino-4-aminy
CA2647671A1 (en) * 2006-03-31 2007-11-01 Massachusetts Institute Of Technology Treatment of tumors expressing mutant egf receptors
US20090099103A1 (en) * 2006-04-05 2009-04-16 Novartis Ag. Combinations of therapeutic agents for treating cancer
EP2094241A4 (en) 2006-11-14 2013-04-17 Ariad Pharma Inc ORAL FORMULATIONS
WO2008124826A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating cancer
WO2008124823A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Method of treating melanoma
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
CN101742910A (zh) * 2007-04-10 2010-06-16 美瑞德制药公司 治疗脑癌的方法
AU2008236995A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Dosages and methods for the treatment of cancer
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2417148T3 (es) 2007-06-08 2013-08-06 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
US8252805B2 (en) * 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
US20100087459A1 (en) * 2008-08-26 2010-04-08 Leonid Metsger Forms of lapatinib compounds and processes for the preparation thereof
CN102356092B (zh) * 2009-03-20 2014-11-05 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
CN110564604B (zh) 2014-01-31 2023-09-29 凸版印刷株式会社 液滴的形成方法、生物分子分析方法及生物分子分析试剂盒
WO2017075495A1 (en) * 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO2001098277A2 (en) * 2000-06-22 2001-12-27 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
BR0214499A (pt) * 2001-12-12 2005-05-10 Pfizer Prod Inc Derivados de quinazolina para o tratamento do crescimento anormal das células
HRP20040530A2 (en) * 2001-12-12 2004-10-31 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
JP4611745B2 (ja) * 2002-11-20 2011-01-12 アレイ バイオファーマ、インコーポレイテッド ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン
EP1575592A1 (en) * 2002-12-18 2005-09-21 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
CO5670356A2 (es) 2006-08-31
RU2006102125A (ru) 2007-09-27
AU2004264726A1 (en) 2005-02-24
WO2005016347A1 (en) 2005-02-24
NO20061252L (no) 2006-05-16
AR045268A1 (es) 2005-10-19
RU2328287C2 (ru) 2008-07-10
KR20080014144A (ko) 2008-02-13
MXPA06001989A (es) 2006-05-17
TW200522966A (en) 2005-07-16
US20050119288A1 (en) 2005-06-02
ZA200600517B (en) 2007-02-28
IL173127A0 (en) 2006-06-11
EP1658080A1 (en) 2006-05-24
BRPI0413745A (pt) 2006-10-24
JP2007502807A (ja) 2007-02-15
SG135193A1 (en) 2007-09-28
KR20060037447A (ko) 2006-05-03
CN1838959A (zh) 2006-09-27

Similar Documents

Publication Publication Date Title
US20050119288A1 (en) Dosing schedule for a novel anticancer agent
KR102871791B1 (ko) 병용 요법
US11096947B2 (en) Combination products with tyrosine kinase inhibitors and their use
CN109069504B (zh) 氨基噻唑化合物及其用途
TW201831188A (zh) 涉及二芳基巨環化合物之組合療法
TW202007396A (zh) Bcl-2抑制劑或Bcl-2/Bcl-xL抑制劑與BTK抑制劑的組合產品及其在預防和/或治療疾病中的用途
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN118369119A (zh) KRAS G12D抑制剂与泛ErbB家族抑制剂的组合疗法
JP2023075161A (ja) 癌の処置
PT2182948E (pt) Utilização de imidazoquinolinas para o tratamento de doenças dependentes do egfr ou doenças que adquiriram resistência a agentes que têm como alvo membros da família egfr
KR20240170920A (ko) Sos1 억제제 및 egfr 억제제를 포함하는 병용 요법
KR20210038366A (ko) Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
JP2016106092A (ja) 組合せ
CN112237579B (zh) 药物组合及其用途
KR20250002214A (ko) Sos1 억제제 및 mek 억제제를 포함하는 병용 요법
CN112843059A (zh) 一种取代丁烯酰胺的应用
CN117615762A (zh) 组合疗法
HK1091745A (en) Dosing schedule for erbb2 anticancer agents
CN115721649A (zh) 抑制突变型egfr的化合物及其应用
EA048458B1 (ru) Способы комбинированной терапии
HK40035225A (en) Pharmaceutical combination and use thereof
HK40055040A (en) Combination therapies

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued